{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:19:18Z","timestamp":1789265958264,"version":"build-2803163510"},"reference-count":14,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T00:00:00Z","timestamp":1500595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["IM103\u2010353"],"award-info":[{"award-number":["IM103\u2010353"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Belatacept use has been constrained by higher rates of acute rejection. We hypothesized that belatacept with low\u2010dose <jats:styled-content style=\"fixed-case\">rATG<\/jats:styled-content> and initial mycophenolate maintenance with conversion to everolimus at 1\u00a0month post\u2010transplant \u00b1 corticosteroids would improve efficacy and maintain safety. Retrospective single\u2010center analysis of the first 44 low immunologic risk kidney transplant recipients treated with this regimen. The cohort was 59% male, mean age at transplant of 57\u00a0years. Diabetes was the most common cause of <jats:styled-content style=\"fixed-case\">ESRD<\/jats:styled-content> (39%). The mean 1\u2010year <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content> was 61.4 (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> 18.4) <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>. There were five acute cellular rejections (11.4%) that occurred in patients who had changed from everolimus to mycophenolate mofetil due to side effects. Thirty\u2010two percent developed <jats:styled-content style=\"fixed-case\">BK<\/jats:styled-content> viremia and 12% developed <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> viremia. There were no cases of <jats:styled-content style=\"fixed-case\">PTLD<\/jats:styled-content>. A novel belatacept regimen with <jats:styled-content style=\"fixed-case\">rATG<\/jats:styled-content> induction and maintenance everolimus demonstrated a low acute rejection rate and maintained an excellent 1\u2010year <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/ctr.13042","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T18:56:46Z","timestamp":1498762606000},"source":"Crossref","is-referenced-by-count":15,"title":["Retrospective evaluation of the efficacy and safety of belatacept with thymoglobulin induction and maintenance everolimus: A single\u2010center clinical experience"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5342-0277","authenticated-orcid":false,"given":"David","family":"Wojciechowski","sequence":"first","affiliation":[{"name":"Division of Nephrology Massachusetts General Hospital  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu","family":"Chandran","sequence":"additional","affiliation":[{"name":"Division of Nephrology University of California San Francisco  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2410-7817","authenticated-orcid":false,"given":"Joshua Y. C.","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Transplant Surgery University of California San Francisco  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minnie M.","family":"Sarwal","sequence":"additional","affiliation":[{"name":"Division of Transplant Surgery University of California San Francisco  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Vincenti","sequence":"additional","affiliation":[{"name":"Division of Nephrology University of California San Francisco  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03785.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506027"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.03005.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04342.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04341.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03338.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12712"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2012.02.003"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03016.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01688.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03129.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31826ec74e"},{"key":"e_1_2_7_14_1","unstructured":"AdamsA Garrett C ChamiA HarlerM et\u00a0al.Belatacept Post\u2010Approval Implementation: A Large Single Center Experience. American Transplant Congress;2013."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13613"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fctr.13042","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.13042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T14:03:48Z","timestamp":1695477828000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.13042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,21]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/ctr.13042"],"URL":"https:\/\/doi.org\/10.1111\/ctr.13042","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,21]]},"article-number":"e13042"}}